The HER2 alteration occurs in 20% – 25% of human breast tumours 3,4 and can be identified by protein overexpression as assessed using immunohistochemistry (ihc) or by gene amplification as assessed using fluorescence in-situ hybridization (fish) or chromogenic in-situ hybridization. This evidence concerns the gene ERBB2 and breast neoplasm.